Accelerate Diagnostics Inc
NASDAQ:AXDX

  • LAST PRICE
    1.6400
  • TODAY'S CHANGE (%)
    -0.0300 (-1.7964%)
  • Bid / Lots
    1.5100/ 1
  • Ask / Lots
    2.0000/ 150
  • Open / Previous Close
    1.6800 / 1.6700
  • Day Range
    1.6000
    1.7800
  • 52 Week Range
    0.7300
    5.2300
  • Volume
    37,260

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 4:33PM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: AXDX
      04:33 PM EST, 11/07/2024 (MT Newswires) -- ...

    • 4:06PM ET on Thursday Nov 07, 2024 by PR Newswire
      Companies Mentioned: AXDX

      Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024.

      https://mma.prnewswire.com/media/727214/Accelerate_Diagnostics_Logo.jpg

      "We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVETM system and the Gram-Negative assay. This quarter also marked a significant milestone with FDA clearance of our Accelerate ArcTM system, a testament to our commitment to breakthrough solutions in diagnostics," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc. "Alongside these advances, we've continued to make meaningful progress in our commercial strategy, all while exercising disciplined financial management, which we believe will help drive sustainable growth for our company," Mr. Phillips continued.

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: AXDX
      Net cash used in operating activities (19,126) (32,441) Cash flows from investing activities: Purchases of equipment (509) (925) Maturities of marketable securities -- 9,695 ---------------------- ---------------------- Net cash (used in) provided by investing activities (509) 8,770 See accompanying notes to condensed consolidated financial statements. ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) Unaudited (in thousands) Nine Months Ended September 30, 2024 2023 Cash flows from financing activities: Proceeds from issuance of Units to related party 4,750 -- Proceeds from issuance of Units 10,232 -- Units offering issuance cost (1,234) -- Proceeds from issuance of common stock to related party -- 4,000 Proceeds from exercise of warrants 502 -- Payments on finance leases (683) (1,357) Proceeds from issuance of 16.00% Notes 15,000 -- Transaction costs related to debt and equity issuances (202) (3,731) Proceeds from issuance of 5.00% Notes -- 10,000 Payment of debt (726) -- -------------------------- -------------------------- Net cash provided by financing activities 27,639 8,912 Effect of exchange rate on cash (451) 16 Decrease in cash and cash equivalents 7,553 (14,743) Cash and cash equivalents, beginning of period 12,138 34,905 -------------------------- -------------------------- Cash and cash equivalents, end of period $ 19,691 $ 20,162 ========================== ========================== Non-cash investing activities: Net transfer of instruments from inventory to property and equipment $ 321 $ 88 Non-cash financing activities: Accrued debt issuance costs $ 566 $ -- Extinguishment of 5.00% Notes through issuance of common stock $ 43 $ 330 Capital contribution from the exchange of secured note and accrued interest through the issuance of common stock with related party $ -- $ 25,363 Exchange of 2.50% Notes and accrued interest for 5.00% Notes $ -- $ 56,893 Debt premium on issuance of 5.00% Notes $ -- $ 6,023 Bifurcated derivative liability $ -- $ 38,160 Extinguishment of derivative liability in connection with extinguishment of 5.00% Notes $ -- $ 380 Issuance of common stock in connection with extinguishment of 5.00% Notes $ -- $ 658 Supplemental cash flow information: Interest paid $ 33 $ -- See accompanying notes to condensed consolidated financial statements.

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: AXDX
      Net cash used in operating activities (19,126) (32,441) Cash flows from investing activities: Purchases of equipment (509) (925) Maturities of marketable securities -- 9,695 ---------------------- ---------------------- Net cash (used in) provided by investing activities (509) 8,770 See accompanying notes to condensed consolidated financial statements. ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) Unaudited (in thousands) Nine Months Ended September 30, 2024 2023 Cash flows from financing activities: Proceeds from issuance of Units to related party 4,750 -- Proceeds from issuance of Units 10,232 -- Units offering issuance cost (1,234) -- Proceeds from issuance of common stock to related party -- 4,000 Proceeds from exercise of warrants 502 -- Payments on finance leases (683) (1,357) Proceeds from issuance of 16.00% Notes 15,000 -- Transaction costs related to debt and equity issuances (202) (3,731) Proceeds from issuance of 5.00% Notes -- 10,000 Payment of debt (726) -- -------------------------- -------------------------- Net cash provided by financing activities 27,639 8,912 Effect of exchange rate on cash (451) 16 Decrease in cash and cash equivalents 7,553 (14,743) Cash and cash equivalents, beginning of period 12,138 34,905 -------------------------- -------------------------- Cash and cash equivalents, end of period $ 19,691 $ 20,162 ========================== ========================== Non-cash investing activities: Net transfer of instruments from inventory to property and equipment $ 321 $ 88 Non-cash financing activities: Accrued debt issuance costs $ 566 $ -- Extinguishment of 5.00% Notes through issuance of common stock $ 43 $ 330 Capital contribution from the exchange of secured note and accrued interest through the issuance of common stock with related party $ -- $ 25,363 Exchange of 2.50% Notes and accrued interest for 5.00% Notes $ -- $ 56,893 Debt premium on issuance of 5.00% Notes $ -- $ 6,023 Bifurcated derivative liability $ -- $ 38,160 Extinguishment of derivative liability in connection with extinguishment of 5.00% Notes $ -- $ 380 Issuance of common stock in connection with extinguishment of 5.00% Notes $ -- $ 658 Supplemental cash flow information: Interest paid $ 33 $ -- See accompanying notes to condensed consolidated financial statements.

  • Oct 25, 2024

Peers Headlines